Text Size

Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00873249
First received: March 31, 2009
Last updated: March 23, 2010
Last verified: March 2010
History of Changes
  Purpose

This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.


Condition
Schizophrenia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Effect of Daily SMS Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Morisky Green Questionnaire [ Time Frame: baseline, at months 3 and 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical Global Impression- Schizophrenia (CGI-SCH) [ Time Frame: baseline, at months 3 and 6 ] [ Designated as safety issue: No ]
  • Register of Adherence to Treatment (RAT) [ Time Frame: baseline, at months 3 and 6 ] [ Designated as safety issue: No ]

Enrollment: 339
Study Start Date: April 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Stabilized outpatients with a diagnosis of schizophrenia

Criteria

Inclusion Criteria:

  • Male or female patients older than 18 years
  • With a diagnosis of schizophrenia (DSM-IV TR criteria)
  • Stabilized out-patients
  • Under oral antipsychotic monotherapy

Exclusion Criteria:

  • Administration of a depot antipsychotic drug
  • Suicide risk
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00873249

Locations
Spain
Research Site
Berga, Barcelona, Spain
Research Site
Sabadell, Barcelona, Spain
Research Site
Santander, Cantabria, Spain
Research Site
Pamplona, Navarra, Spain
Research Site
Calatayud, Zaragoza, Spain
Research Site
Alicante, Spain
Research Site
Almeria, Spain
Research Site
Barcelona, Spain
Research Site
Burgos, Spain
Research Site
Cordoba, Spain
Research Site
Granada, Spain
Research Site
Leon, Spain
Research Site
Lerida, Spain
Research Site
Madrid, Spain
Research Site
Malaga, Spain
Research Site
Murcia, Spain
Research Site
Oviedo, Spain
Research Site
Palma Mallorca, Spain
Research Site
Salamanca, Spain
Research Site
Sevilla, Spain
Research Site
Tarragona, Spain
Research Site
Toledo, Spain
Research Site
Valencia, Spain
Research Site
Valladolid, Spain
Research Site
Zamora, Spain
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: Teresa Diez, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00873249     History of Changes
Other Study ID Numbers: NIS-NES-DUM-2007/3
Study First Received: March 31, 2009
Last Updated: March 23, 2010
Health Authority: Spain: Ethics Committee

Keywords provided by AstraZeneca:
Schizophrenia
Therapeutic adherence
Short message system
Mobile phone

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 23, 2013